[Successful open vascular-surgical supracoeliac anastomosis of a bifurcational prosthesis with simultaneous prosthetomesenteric and renal revascularisation in Leriche's syndrome with high occlusion]. / Erfolgreiche offen-chirurgische, suprazöliakale Bifurkationsprothesen-implantation mit simultaner prothetomesenterialer und -renaler Revaskularisation bei hohem Leriche-Syndrom.

BACKGROUND: Based on an extraordinary case -report on a patient with almost symptomless supramesenteric occlusion of the aorta, the successful management and favourable outcome including almost normalised renal function (in addition to appropriate diagnostic and operative tactics) achieved by a technically challenging vascular-surgical intervention and subsequent intensive medical and nephrological care are described. RESULTS: In a 49-year-old male patient, a "high" aortic occlusion just below the branching of the coeliac trunk with arterial perfusion of the abdomen and the lower extremities via arterial collaterals from the 4 (th) to 6 (th) intercostal arteries was diagnosed. Both renal arteries were occluded leading to a consecutive renal insufficiency with need for dialysis and renovascularly induced hypertension. However, a residual perfusion of the parenchyma of the left kidney was detectable. Therapeutic measures comprised, after haemodialysis with accompanying antihypertensive medication, open supracoeliac aortobifemoral implantation of a prosthesis, revascularisation of the left renal artery (prosthetic bypass) and prostheticomesenteric bypass implantation. Postoperatively, a reestablished renal perfusion was observed in spite of the preoperatively prolonged lack of appropriate arterial perfusion (last dialysis, 11 (th) POD / discharge, 18 (th) POD). At 3 months postoperatively, the patient reported an increase of his body weight of 8 kg (at 6 months, 20 kg; improved but still elevated laboratory parameters indicating renal insufficiency; RR within normal range). Postinterventional MR angiography revealed a regular perfusion of the bifurcational prosthesis and of the bypasses to the superior mesenteric and left renal arteries. CONCLUSION: This exemplary case demonstrates impressively the individual therapeutic chances, options and the potential in the diagnostic and therapeutic interdisciplinary management and its combined expertise. The clinical course in this case indicates that the assessment of the arterial blood supply has to be included in the diagnostic of an acute renal insufficiency associated with anuria. If there is a minimal residual perfusion, which might just be sufficient for maintenance of structural integrity, there is a real chance for a restitution of renal function after successful revascularisation.

Cardiac troponin T predicts mortality in patients with end-stage renal disease.

BACKGROUND: Patients with end-stage renal disease have a high risk of premature death, mainly as the result of cardiovascular disease (CVD), which is not sufficiently explained by the conventional risk factors. We therefore prospectively investigated total mortality and cardiovascular events in 102 patients on hemodialysis and assessed the prognostic value of baseline disease status and laboratory variables including total homocysteine and cardiac troponin T. METHODS AND RESULTS: Patients were followed for 2 years or until their first event of CVD (for outcome variable cardiovascular events, n=33) or death (for outcome variable total mortality, n=28). Survival was computed by the Kaplan-Meier method. Cox proportional hazards model was used to determine independent predictors of CVD events or total mortality. Cardiac troponin T emerged as the most powerful predictor of mortality, resulting in an almost 7-fold risk increase at concentrations >0.10 ng/mL (hazard ratio 6.85, 95% CI 3. 04 to 15.45). Total homocysteine level greater than median was also associated with mortality (hazard ratio 2.44, 95% CI 1.10 to 5.40). These hazard ratios did not change substantially after adjustment for other risk factors. Significant predictors for CVD events were baseline diabetes, cerebrovascular disease, serum glucose, and triglycerides. After adjustment, only glucose and triglycerides remained significantly related to CVD events (hazard ratio with 95% CI 1.33 [1.12 to 1.57] and 1.14 [1.04 to 1.26], respectively, for a 1-mmol/L increase in concentration). CONCLUSIONS: We conclude that total homocysteine and particularly cardiac troponin T are important predictors of mortality in patients with end-stage renal disease, whereas other laboratory variables and baseline disease status have less prognostic value.

Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease.

BACKGROUND: Elevated concentrations of homocysteine are associated with an increased risk for cardiovascular disease. Reasons for elevated homocysteine concentrations are folate or vitamin B12 deficiency, renal disease or genetic abnormalities. A high prevalence of hyperhomocysteinemia is found in patients with end-stage renal disease (ESRD). Since these patients are also at increased risk for vitamin deficiency, a supplementation study comparing two doses of folic acid was performed in patients with ESRD treated with maintenance hemodialysis or with peritoneal dialysis. PATIENTS AND METHODS: Patients undergoing hemodialysis (n = 70) or peritoneal dialysis (n = 12) were supplemented with 2.5 mg or 5 mg folic acid (three times per week after each dialysis treatment) for four weeks in a parallel study design. In 20 hemodialysis patients, the effect of folic acid withdrawal was observed after four weeks. RESULTS: Both supplementation schemes reduced homocysteine to a similar extent (35%) but did not normalize homocysteine concentrations in the majority of patients. Dialysis also had a strong homocysteine lowering effect. After supplementation, 74% of the hemodialysis patients had post-dialysis homocysteine concentrations within the reference range (<16 micromol/l). Homocysteine concentrations remained decreased in 20 patients four weeks after withdrawal of folic acid supplementation. CONCLUSIONS: It is concluded that supplementation with 2.5 or 5 mg folic acid has a similar effect on homocysteine concentrations to supplementation regimens using 15 mg folic acid supplements. In contrast to the effect of folic acid supplementation in subjects with normal renal function, folic acid supplementation does not normalize homocysteine concentrations in ESRD patients.

[Treatment of plasmacytoma with hyperviscosity syndrome]. / Die Behandlung des Plasmozytoms mit Hyperviskositätssyndrom.

It is reported on the treatment of three patients with a hyperviscosity syndrome in IgG-plasmocytoma. Before every polychemotherapy cycle a plasma exchange was carried out, when the total protein in the serum and the immunoglobulins were essentially increased and clinical symptoms of the hyperviscosity syndrome were existing. The results and the possible effects on the efficacy of the therapy with cytostatic agents are discussed. In the light of our experiences we can recommend the membrane plasma filtration treatment as symptomatic therapeutic measure in the hyperviscosity syndrome.